LitAlert ~~ GeneLit.com

    • Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use.
    • Abbotts R, Dellomo AJ, Rassool FV.
    • Cancers (Basel). 2022 May 26;14(11):2640. doi: 10.3390/cancers14112640.
    • Imaging PARP with [18F]rucaparib in pancreatic cancer models.
    • Chan CY, Chen Z, Destro G, Veal M, Lau D, O'Neill E, Dias G, Mosley M, Kersemans V, Guibbal F, Gouverneur V, Cornelissen B.
    • Eur J Nucl Med Mol Imaging. 2022 May 26. doi: 10.1007/s00259-022-05835-4. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Stable CDK12 knock-out ovarian cancer cells do not show increased sensitivity to cisplatin and PARP inhibitor treatment.
    • Chilà R, Guffanti F, Chiappa M, Panini N, Conconi D, Rinaldi A, Cascione L, Bertoni F, Fratelli M, Damia G.
    • Front Oncol. 2022 May 24;12:903536. doi: 10.3389/fonc.2022.903536.
    • Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment.
    • Moyret-Lalle C, Prodhomme MK, Burlet D, Kashiwagi A, Petrilli V, Puisieux A, Seimiya H, Tissier A.
    • Cancer Sci. 2022 May 9. doi: 10.1111/cas.15389. Epub ahead of print.
    • [2. Paradigm Shift from the Experiences of Hereditary Breast Cancer].
    • Yamauchi H.
    • Nihon Hoshasen Gijutsu Gakkai Zasshi. 2022;78(5):531-534. Japanese. doi: 10.6009/jjrt.2022-2022.
    • [Article in Japanese]
  • LitAlert ~~ GeneLit.com

    • Exploiting replication gaps for cancer therapy.
    • Cong K, Cantor SB.
    • Mol Cell. 2022 May 4:S1097-2765(22)00386-0. doi: 10.1016/j.molcel.2022.04.023. Epub ahead of print.
    • Review
    • Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
    • Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T.
    • J Gynecol Oncol. 2022 May 3. doi: 10.3802/jgo.2022.33.e55. Epub ahead of print.

    Trial ID: jRCT2031210264: Phase 2 Study to Evaluate the Efficacy and Safety of Niraparib in Recurrent or Persistent Rare Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052). (Japanese Registry of Clinical Trials)

    • Pregnancy Hormone Mediated Tumorigenesis in BRCA1 Defective Breast Cancers.
    • Krishnan N, Yadev I, Anandan J, Patra D, Rajan A, Srinivas P.
    • FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.0R373.
    • Conference abstract
  • LitAlert ~~ GeneLit.com

    • MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation.
    • Vajen B, Bhowmick R, Greiwe L, Schäffer V, Eilers M, Reinkens T, Stalke A, Schmidt G, Fiedler J, Thum T, DeLuca DS, Hickson ID, Schlegelberger B, Illig T, Skawran B.
    • Int J Mol Sci. 2022 May 4;23(9):5131. doi: 10.3390/ijms23095131.
    • Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
    • Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T.
    • J Gynecol Oncol. 2022 May 3. doi: 10.3802/jgo.2022.33.e55. Epub ahead of print.

    Trial ID: jRCT2031210264: Phase 2 Study to Evaluate the Efficacy and Safety of Niraparib in Recurrent or Persistent Rare Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052). (Japanese Registry of Clinical Trials)

    • Estrogen and BRCA1 deficiency synergistically induce breast cancer mutation-related DNA damage.
    • Chen J, Liu J, Zeng P, Zhao C, Liu X, Sun J, Wang J, Fang P, Chen W, Ding J.
    • Biochem Biophys Res Commun. 2022 May 2;613:140-145. doi: 10.1016/j.bbrc.2022.04.142. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells.
    • Baquero JM, Marchena-Perea E, Mirabet R, Torres-Ruiz R, Blanco-Aparicio C, Rodríguez-Perales S, Helleday T, Benítez-Buelga C, Benítez J, Osorio A.
    • Front Oncol. 2022 May 10;12:888810. doi: 10.3389/fonc.2022.888810.
    • Computational structural assessment of BReast CAncer type 1 susceptibility protein (BRCA1) and BRCA1-Associated Ring Domain protein 1 (BARD1) mutations on the protein-protein interface.
    • Thirumal Kumar D, Udhaya Kumar S, Jain N, Sowmya B, Balsekar K, Siva R, Kamaraj B, Sidenna M, George Priya Doss C, Zayed H.
    • Adv Protein Chem Struct Biol. 2022;130:375-397. doi: 10.1016/bs.apcsb.2022.02.003. Epub 2022 Apr 21.
  • LitAlert ~~ GeneLit.com

    • Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells.
    • Feng L, Yang W, Zhao H, Bakkum-Gamez J, Sherman ME, Kannan N.
    • Methods Mol Biol. 2022 [First Online: 2022 May 5];2429:445-454. doi: 10.1007/978-1-0716-1979-7_30.
    • Alterations in homologous recombination repair genes in prostate cancer brain metastases.
    • Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins SA, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch H, Thalmann G, Ng CKY, Gillessen S, Piscuoglio S, Rubin MA.
    • Nat Commun. 2022 May 3;13(1):2400. doi: 10.1038/s41467-022-30003-5.
    • Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
    • Xu Y, Wu H, Huang L, Zhai B, Li X, Xu S, Wu X, Zhu Q, Xu Q.
    • Eur J Med Chem. 2022 Apr 27;237:114417. doi: 10.1016/j.ejmech.2022.114417. Epub ahead of print.
    • A South African Indian population group dataset for breast cancer and BRCA1/2 variants.
    • Combrink HMVE, van der Merwe NC, Katarya R, de Wet K, Motloung MH.
    • Data Brief. 2022 Apr 14;42:108180. doi: 10.1016/j.dib.2022.108180.

    Original research:

    Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study.

    • BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    • Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, McAlpine JN, Toomey S, Huntsman DG, Grogan L, Breathnach O, Morris P, Carey MS, Scott CL, Hennessy BT.
    • Br J Cancer. 2022 Apr 30. doi: 10.1038/s41416-022-01823-5. Epub ahead of print.
    • Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.
    • Li J, Lan M, Peng J, Xiong Q, Xu Y, Yang Y, Zhou Y, Liu J, Zeng Z, Yang X, Zhang Z, Zhang P, Zhu Q, Wu W.
    • Genes (Basel). 2022 Apr 30;13(5):803. doi: 10.3390/genes13050803.